Jia Liu – CEO, DreamCIS, South Korea
Jia Liu, CEO of DreamCIS, a Korean CRO, part of the Chinese company Tigermed, talks about her vision for DreamCIS to be “the CRO everybody wants to work with”. Liu…
Address: 1010, 10F, Jeokseon Hyundai Bld, 80, Jeokseon-dong, Seoul, Jongno-gu, Seoul,Republic of Korea
Tel: +82 2 2010 4500
DreamCIS is a full service contract research organization (CRO) that offers to the pharmaceutical companies, bio venture companies, medical device manufacturers, and functional food producers. DreamCIS provides clinical trial services for a broad and detailed range of therapeutic area in accordance with the standard operating procedures consistent with both Republic of Korean regulations and global standards including ICH-GCP guidelines. DreamCIS aims at enhancing both the reliability of its clinical services provided and product competitiveness by striving to maintain the consistency in quality of its services. Accomplishing this goal will no doubt enable us to contribute to the health of the people. DreamCIS has its Specialist Advisory Committee comprised of high-level specialists in their field to provide comprehensive and specialized clinical services. The community in partnership with DreamCIS include Ionet Republic of Korea which was organized by DreamCIS exclusively for the development of Web-CRF program, DreamCIS’s patented product, Yonsei University Department of Biostatics Medical College, YOU & ME Patent and Law Firm, Yonsei University Research Institute of Food & Nutrition, SMSI (Seoul Medical Science Institute), Biotoxtech Co.,Ltd. DreamCIS has launched a business partnership with Gleneagles CRC (Singapore), a leading CRO/SMO in the Asia Pacific region, with the aim to conduct multi-national clinical trials seamlessly for multi-national customers as well. Founded in April, 2000, DreamCIS has ever since been dedicated to providing a full range of clinical services for a number of customers/sponsors, including major pharmaceutical companies, multi-national pharmaceutical companies, bio venture companies, health food producers, and medical device manufacturers in Republic of Korea. DreamCIS will continue striving to provide customers reliable clinical trial data while conducting all of clinical trials using our expertise and significant experience in the field of clinical trials.
It aims to provide customers differentiated services based on strict quality control in a scientific and systematic manner and high ethical standards. DreamCIS’ key service areas include: ㆍClinical trials for medicines / medical devices ㆍPost-marketing surveillance (PMS) ㆍQA audit ㆍData management and Statistical analysis ㆍHealth functional foods Trials ㆍPre-clinical trials management ㆍTraining and dispatch of clinical research nurses
Jia Liu, CEO of DreamCIS, a Korean CRO, part of the Chinese company Tigermed, talks about her vision for DreamCIS to be “the CRO everybody wants to work with”. Liu…
Olive Healthcare is a startup developing wellness and medical devices services for the quantitative measurement of body composition, an integral part of the new healthcare paradigm based on prevention. Here,…
A Korean research team at Ulsan National Institute of Science and Technology (UNIST) have developed a cunning technology for treatments that attack cancer cells. Treatments that travel through the…
From Wednesday 31st October to Friday 2nd November, Seoul hosted the KoNECT-MFDS International conference, promoting South Korea’s clinical research capabilities on a global platform. The fourth of its kind, the…
Celltrion Healthcare, the marketing arm of the biopharmaceutical company Celltrion won a huge deal in France last Friday (2nd November 2018) with big tenders for Herzuma, a biosimilar of Roche’s…
Korea is fast becoming a big player in the pharmaceutical industry, especially within the biotech arena. With 4% of the total pipelines in the world, the country is showing strong…
Korean Pharma company, Hanmi has won orphan drug status this week from the US Food and Drug Administration (FDA) for HM43239, a drug for the treatment of acute myeloid leukaemia…
Local flagship company Boryung has found success with its newly developed angiotension receptor blocker (ARB) Kanarb. Nine molecules currently exist worldwide in this category of antihypertensives, and Kanarb is currently…
The growth of clinical trials in Korea has been remarkable in recent years. The number of clinical trials performed by multinationals has shot up from five in 2000 to 303…
Korea’s economy has been dominated for decades by chaebols, large family-owned business conglomerates like Samsung, Hyundai, and LG, known for their hierarchical structures and success in Korea’s traditional sectors. However,…
Medytox is the most valuable pharmaceutical business in Korea, with a highly successful botulinum toxin product on the market, and can only grow further when they finish development of their…
“When I left Janssen, I never imagined joining a Korean company,” recalls Choi Tae-Hung, sipping a freshly brewed yujacha tea in his office on a crisp autumn morning as he…
Minister Moon discusses the results of his recent state visit to the Middle East with Korea’s President, and Korea’s assets and potential as a global healthcare partner in developing and…
See our Cookie Privacy Policy Here
